About PCROWD, Dana-Farber’s tissue-banking study for patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes
PCROWD (“Precursor CROWDsourcing”) – a tissue banking and clinical information study and repository – is an indispensable component of the blood cancer research pipeline.
The main objective of PCROWD is to collect, process, store and study tissue samples from patients with blood cancer precursor conditions. Some of the precursor conditions being studied in PCROWD are monoclonal gammopathy of undetermined significance (MGUS); smoldering multiple myeloma (SMM) or smoldering Waldenström’s macroglobulinemia; early myelodysplastic syndrome (MDS); monoclonal B-cell lymphocytosis; and myeloproliferative neoplasms (MPN).
Patients with precursor blood conditions have traditionally been told to “watch and wait” – and have not received treatment until their condition has progressed to cancer. The PCROWD study will follow these patients at the same time that they are followed clinically – providing scientists with a rich source of samples and data.
PCROWD is a project of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers – with the ultimate aim of developing targeted therapeutic agents that can eliminate the early clones of disease.
Responding to the need to create a large database of clinical and epidemiological information from patients with precursor conditions, research scientists at Dana-Farber established CPOP in 2014. This first-of-its-kind clinic focuses on identifying precursor blood conditions in patients – as well as on gathering clinical and epidemiological information that will fuel research to identify novel therapeutic options that prevent or delay disease progression.
This bold initiative by Dana-Farber is the first in the world attempting to change the paradigm of management of patients with precursor conditions that may lead to hematological malignancies.
Copyright © 2017 CancerConnect. All Rights Reserved.
More cancer news.